Drug Trial Radar · NCT00735397
Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Last checked: Nov 19, 2026Latest source record: Mar 14, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,218
Actual
Start
Oct 2008
Primary completion
Sep 2014
Study completion Sep 2014
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Aug 14, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the safety and tolerability of perampanel (up to 12 mg/day) given as adjunctive treatment in subjects with refractory partial seizures and to evaluate the maintenance of effect of perampanel for the control of refractory partial seizures.
Conditions
- Epilepsy
Interventions
perampanelDrug
Perampanel 2 mg to 12 mg, once daily in the Open-Label Extension (OLE) study up to approximately 5 years
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Non-Serious Adverse Events (AEs) and Treatment-emergent Serious Adverse Events (SAEs)Time frame: From date of first dose of perampanel up to 30 days after the last dose of perampanel or up to approximately 5 years.
Locations
239 sites in 39 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Phoenix, Arizona
Site not named
Phoenix, Arizona
Site not named
Tucson, Arizona
Site not named
Little Rock, Arkansas
Site not named
Fresno, California
Site not named
San Francisco, California
Site not named
Ventura, California
Site not named
Denver, Colorado
Site not named
Fort Collins, Colorado
Site not named
Washington D.C., District of Columbia
Site not named
Gulf Breeze, Florida
Site not named
Jacksonville, Florida
Site not named
Jacksonville, Florida
Site not named
Orlando, Florida
Site not named
Tallahassee, Florida
Site not named
Tampa, Florida
Site not named
Atlanta, Georgia
Site not named
Suwanee, Georgia
Site not named
Boise, Idaho
Site not named
Indianapolis, Indiana
Site not named
Ames, Iowa
Site not named
Lexington, Kentucky
Site not named
Houma, Louisiana
Site not named
Baltimore, Maryland
Site not named
Bethesda, Maryland
Site not named
Hattiesburg, Mississippi
Site not named
Chesterfield, Missouri
Site not named
Kansas City, Missouri
Site not named
St Louis, Missouri
Site not named
Albany, New York
Site not named
Buffalo, New York
Site not named
Great Neck, New York
Site not named
Lawrence, New York
Site not named
New York, New York
Site not named
Rochester, New York
Site not named
Syracuse, New York
Site not named
Asheville, North Carolina
Site not named
Akron, Ohio
Site not named
Cincinnati, Ohio
Showing 40 of 239 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.